SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
Phase 1ActiveDevelopment Stage
Medulloblastoma
Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Jul 1, 2022 → Feb 28, 2030
About SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years is a phase 1 stage product being developed by Brain Biotech for Medulloblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT04978727. Target conditions include Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04978727 | Phase 1 | Active |
Competing Products
9 competing products in Medulloblastoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2940680 + LY2940680 | Eli Lilly | Phase 1 | 33 |
| LDE225 + TMZ | Novartis | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1/2 | 41 |
| Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine | Brain Biotech | Phase 1 | 25 |
| Modified Measles Virus + Modified Measles Virus Lumbar Puncture | Brain Biotech | Phase 1 | 25 |
| CX 4945 | Brain Biotech | Phase 1/2 | 33 |
| PEP-CMV | Brain Biotech | Phase 1 | 25 |
| Apatinib Combined With Temozolomide and Etoposide Capsules | Brain Biotech | Phase 2 | 44 |
| Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics | Brain Biotech | Phase 2 | 44 |